Establishing a Flow Process to Coumarin-8-Carbaldehydes As Important Synthetic Scaffolds

Total Page:16

File Type:pdf, Size:1020Kb

Establishing a Flow Process to Coumarin-8-Carbaldehydes As Important Synthetic Scaffolds FULL PAPER DOI: 10.1002/chem.201201039 Establishing a Flow Process to Coumarin-8-Carbaldehydes as Important Synthetic Scaffolds Jaroslav Zak,[a, c] David Ron,[b] Elena Riva,*[a] Heather P. Harding,[b] Benedict C. S. Cross,[b] and Ian R. Baxendale[a] Abstract: Despite their usefulness as fluorophores and synthetic precursors, effi- cient and reliable routes to coumarin-8-carbaldehydes are lacking. We describe Keywords: coumarins · flow here a high-yielding continuous flow synthesis that requires no manual intermedi- chemistry · heterocycles · micro- ate purification or work-up, giving access to multigram quantities of the aldehyde reactors · solid-supported reagents product. Introduction the ultraviolet region and exhibiting potent fluorescence and luminescence.[2] In addition, they possess a wide range Coumarins are a general structural class of aromatic hetero- of biological activities and have long been considered attrac- cycle defined by the naturally occurring parent compound tive drug scaffolds being used in the treatment of viral infec- (Figure 1), which was first isolated in 1822 from Tonka tions,[3] neurodegenerative diseases,[4] oedema,[5] inflamma- beans (Dipteryx odorata).[1] Molecules possessing the 2H- tion, and as hepatoprotective agents and antioxidants.[6] chromen-2-one core display a diverse range of interesting Indeed, several coumarins derivatives[7] (Figure 1) have al- properties—many are highly coloured, absorbing strongly in ready found pharmaceutical application as vitamin K antag- onists (Warfarin), anticoagulants (Phenprocoumon), antibi- otics (Novobiocin) and antispasmodics (Hymecromone). Furthermore, their utilisation in the fight against cancer is another prominent area, with both natural and synthetic coumarins showing promising activity in in vivo rat models and importantly against malignant human cell lines.[8] Apart from their medicinal applications, coumarins have also found use as sunscreen ingredients,[9] microbiological mark- ers,[10] textile and laser dyes,[11] fluorescent labels[12] and, more recently, as solar cell sensitisers. As a consequence of their general functionality many synthetic methods for their preparation have been reported.[13] However, one particular functional pattern that despite its Figure 1. Coumarin and coumarin derivatives of pharmaceutical impor- simple chemical architecture has proven challenging to tance. access reliably is the 7-hydroxycoumarin-8-carbaldehyde (e.g., 5a, Scheme 1).[14] This is an important structure motif with the juxtaposed formyl and phenoxy groups imparting [a] J. Zak, Dr. E. Riva, Dr. I. R. Baxendale Department of Chemistry enhanced fluorescent characteristics and enabling easy as- University of Cambridge sembly of Schiff base Salen ligands which have found many Lensfield Road, Cambridge, CB2 1EW (UK) applications in diagnostic and detection systems.[15] Histori- E-mail: [email protected] cally, installation of the formyl unit is achieved through [b] Prof. D. Ron, Dr. H. P. Harding, Dr. B. C. S. Cross functionalization of the corresponding 7-hydroxycoumarin University of Cambridge Metabolic Research Laboratories [16] [17] Level 4, Institute of Metabolic Science using a Gattermann–Koch, Reimer–Tiemann, Vilsmei- [18] [14] Box 289, Addenbrookes Hospital er–Haack or Duff reaction. Unfortunately, these meth- Cambridge, CB2 0QQ ods all suffer from poor conversion and often require exten- [c] J. Zak sive work-up leading to further loss of yield and resulting in Current address: Ludwig Institute for Cancer Research an overall inefficient process (Table 1). Requiring access to University of Oxford large quantities of 5a as a biological probe[23] we decided to Old Road Campus Research Building Oxford, OX3 7DQ (UK) evaluate alternative synthesis protocols. Supporting information for this article is available on the WWW We have found that the application of flow processing under http://dx.doi.org/10.1002/chem.201201039. technologies[24] offers several advantages for the synthesis of Chem. Eur. J. 2012, 18, 9901 – 9910 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 9901 streams can be readily facilitated by the incorporation of fixed bed supported reagent cartridges and in-line scaveng- ing columns.[26] Such an approach appeared to us to be ideal for achieving a fast, reliable and readily scalable route to various coumarin carbaldehydes. Results and Discussion Having considered several potential routes we selected two complementary strategies (Scheme 1) which we believed would deliver high yields of the desired products and gain significant efficiencies by adoption of flow processing tech- nologies. However, in order to first facilitate a direct com- parison of the routes against the pre-existing literature methods both proposed sequences were evaluated using standard batch conditions. The basic route development and reaction optimisation was thus conducted on the basic target structure 5a.The first step of both synthetic pathways is common and involves the formation of the coumarin core. This was achieved using [27] Scheme 1. Proposed routes to 7-hydroxy-4-methyl-2-oxo-2H-chromene-8- a Pechmann condensation reaction. A protocol using tri- carbaldehyde (5a). fluoroacetic acid (TFA) as a catalyst was identified being both high-yielding and a generic method of preparation from simple readily available starting materials; resorcinols and acetoacetate derivatives. From this reaction numerous Table 1. Data of comparative yields for the synthesis of 7-hydroxy- coumarin structures. coumarin derivatives were prepared in good yields and ex- cellent regioselectivity (Table 2) when heated at 1008C for Product Reaction Yield [%] Ref. 1 h under microwave irradiation. Using this protocol, only one coumarin derivative failed to form with the anticipated Duff reaction[a] 22 [19] regiocontrol. Thus attempts to prepare the corresponding 2H-chromen-2-one from orcinol and ethyl acetoacetate [28] 5a (Table 2, entry 7) gave compound 1g instead of the ex- 5a Duff reaction[a] 20 [14d]ACHTUNGRE pected 7-hydroxy-4,5-dimethyl-2H-chromen-2-one; the [a] 5a Duff reaction 15 [20] structure of 1g was unambiguously confirmed by X-ray crys- [a] 5a Duff reaction 15 [21] tallography (see the Supporting Information). This is an in- 5a Duff reaction[a] 22 [14b]ACHTUNGRE teresting result as under many alternative reaction condi- tions 7-hydroxy-4,5-dimethyl-2H-chromen-2-one is the only [a] Duff reaction 60 [22] product isolated often in exceptionally high yield.[29] Indeed, [30] following a similar protocol but using H2SO4 as the acid catalyst we also isolated the 7-hydroxy coumarin derivative 1g. Vilsmeier reaction[b] 54 [18a]ACHTUNGRE Following the Pechmann cyclisation the two pathways di- verge (Scheme 1). In Route A the installation of the formyl group is provided for through alkene 4a acting as a latent Vilsmeier reaction[b] 84 [18b]ACHTUNGRE carbonyl group revealed by ozonolysis. The proceeding alke- nylation of the aryl ring occurs by a standard allylation of the phenol (1a!2) followed by a Claisen rearrangement Reaction conditions: [a] 1) hexamethylene tetramine, glacial acetic acid, and metal catalysed isomerisation to yield the necessary 60–808C, 2) HCl. [b] N-methylformanilide, POC13, dichloroethane, 70– conjugated alkene 4a. Alternatively Route B involved an 758C. aminoalkylation of the coumarin followed by N-oxidation and a regioselective Polonovski reaction leading to an inter- complex natural products and their derivatives.[25] Of partic- mediate benzylic iminium species. Direct iminium hydrolysis ular value is the possibility of carrying out two or more se- would then furnish the corresponding aldehyde 5a. Each quential reactions with no or minimal intermediate workup transformation of both sequences was high yielding and fur- and purification between transformations. Indeed, the con- nishes adequately clean material for further processing with- tinuous processing and downstream clean-up of reaction out the need for extensive purification. 9902 www.chemeurj.org 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Chem. Eur. J. 2012, 18, 9901 – 9910 Flow Process to Coumarin-8-Carbaldehydes FULL PAPER Table 2. Synthesized coumarin-carbaldehydes and their synthetic intermediates. Entry Starting Starting Pechmann Mannich N-Oxidation Polonovski material material reaction product reaction product reaction product reaction product 1 1a (quantitative yield) 6a (86%) 7a (31%) 5a (44 %) 2 1b (92%) 6b (70 %) 7b (57%) 5b (41%) 3 1c (quantitative yield) 6c (74 %) 7c (53%) 5c (52%) 4 1d (quantitative yield) 6d (77 %) 7d (71%) 5d (79%) 5 1e (97%) 6e (99%) 7e (36%) 5e (67 %) 6 No reaction 1f(96%) 7 No reaction 1g (72%) Route A batch conditions: The allylation step proceeded and then the resulting THF solution directly subjected to smoothly in essentially quantitative yield using K2CO3 in the ozonolysis conditions. Treatment with ozone gave acetone under mild conditions (608C, 1 h), aqueous extrac- a rapid and clean conversion to the corresponding aldehyde tion to remove inorganic salts was the only work-up necessa- 5a in 20 min as determined by TLC analysis. The intermedi- ry. The subsequent [3,3]-sigmatropic rearrangement was ate ozonide was subsequently cleaved by treatment with found to require elevated temperatures (2008C) and gener- a polymer-supported triphenylphosphine equivalent (PS- ated a mixture of two isomers (3a/3b 9:2) albeit these could PPh2, 3 equiv) giving the desired product in 91% isolated be readily separated by column chromatography (note that yield after filtration
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Coumarin-Piperazine Derivatives As Biologically Active Compounds
    Saudi Pharmaceutical Journal 28 (2020) 220–232 Contents lists available at ScienceDirect Saudi Pharmaceutical Journal journal homepage: www.sciencedirect.com Review Coumarin-piperazine derivatives as biologically active compounds Kinga Ostrowska Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02 097 Warsaw, Poland article info abstract Article history: A number of psychiatric disorders, including anxiety, schizophrenia, Parkinson’s disease, depression and Received 3 May 2019 others CNS diseases are known to induce defects in the function of neural pathways sustained by the neu- Accepted 29 November 2019 rotransmitters, like dopamine and serotonin. N-arylpiperazine moiety is important for CNS-activity, par- Available online 7 December 2019 ticularly for serotonergic and dopaminergic activity. In the scientific literature there are many examples of coumarin-piperazine derivatives, particularly with arylpiperazines linked to a coumarin system via an Keywords: alkyl liner, which can modulate serotonin, dopamine and adrenergic receptors. Numerous studies have Coumarin revealed that the inclusion of a piperazine moiety could occasionally provide unexpected improvements Arylpiperazinyl moiety in the bioactivity of various biologically active compounds. The piperazine analogs have been shown to Biological activity have a potent antimicrobial activity and they can also act as BACE-1 inhibitors. On the other hand, arylpiperazines linked to coumarin derivatives have been shown to have antiproliferative activity against leukemia, lung, colon, breast, and prostate tumors. Recently, it has been reported that coumarin- piperazine derivatives exhibit a Fneuroprotective effect by their antioxidant and anti-inflammatory activ- ities and they also show activity as acetylcholinesterase inhibitors and antifilarial activity. In this work we provide a summary of the latest advances in coumarin-related chemistry relevant for biological activity.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Biological Potentials of Hymecromone-Based Derivatives: a Systematic Review
    Sys Rev Pharm 2020;11(11):438-452 BA miulotifacleotedgreviewcjaourlnalpin tohe ftieled ofnphtarmiacyls of Hymecromone-based derivatives: A systematic review *, PYhaassrmeraFceauktrici aMl uCshteamfaistNryooDreapTarhtammenetr, ACbodllueglaezoizf Pharmacy, Mosul University, Nineveh, Iraq. Corresponding Author: [email protected] ABSTRACT Keywords: Coumarin-based derivatives occupy a prominent position in many fields Hymecromone, Antimicrobial, Antioxidant, Anti-inflammatory, related to medicine and industry. This can be attributed to their multilateral Canotritruemsopro, anndtievnircael, cardio protective. biological activities and diversity of chemical features. Among coumarin-based Yasser Fakri Mustafa derivatives, hymecromone (7-hydroxy-4-methylcoumarin) has attracted great : attention from the medicinal chemists. In addition to its ease preparation, this synthetic coumarin, which is known chemically as 7-hydroxy-4-methyl-2H- Pharmaceutical Chemistry Department, College of Pharmacy, Mosul chromen-2-one, possesses a phenolic hydroxyl group that considers as one of University, Nineveh, Iraq. the most derivatiable functional groups. In the literature, many scientific [email protected] papers described the synthesis and biological activities of hymecromone- *Corresponding author: Yasser Fakri Mustafa email-address: based derivatives. This systematic review focused on the synthesis of these derivatives and description of their biological potentials, especially those related to the antimicrobial, antioxidant, antitumor,
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Co-Crystal Structure of Mixed Molecules
    International Journal of Physical Sciences Vol. 7(10), pp. 1564 - 1570, 2 March, 2012 Available online at http://www.academicjournals.org/IJPS DOI: 10.5897/IJPS11.1772 ISSN 1992 - 1950 © 2012 Academic Journals Full Length Research Paper Co-crystal structure of mixed molecules Abdul Amir H. Kadhum2, Ahmed A. Al-Amiery1,2*, Hamdan A. Aday1, Yasamin K. Al-Majedy Ali A. Al-Temimi1, Redah I. Al-Bayati3 and Abu Bakar Mohamad2 1Department of Chemical and Process Engineering, Faculty of Engineering and Built Environment, Universiti of Kebangsaan Malaysia, Bangi, Selangor 43600, Malaysia 2Biotechnology Division, Applied Science Department, University of Technology, Baghdad 10066, Iraq. Accepted 13 January, 2012 Based on the fundamentals of organic chemistry, the approach leads to the corresponding amides in good yields which were the reaction of esters with primary amines. In our laboratory, there was no reaction when we tried to react methyl 2-(2-oxo-2H-chromen-7-yloxy)acetate with 2-(2-aminophenyl) benzothiazole). Although the spectral data was so enough for validation of the structure of the product but in the thin layer chromatography (TLC) test, there still appear two spots for the reactant (no reaction); so only X-ray single crystallography will solve this problem and identify the structure of this shiny light brown crystal. Co-crystal structure was synthesized in methanolic solution from methyl 2-(2- oxo-2H-chromen-7-yloxy)acetate and 2-(2-aminophenyl)benzothiazole). Single X-ray crystallography was studied and it was found that there was no hydrogen bonding between the molecules, moreover, the co-crystal is very stable.
    [Show full text]
  • Research on Identification of Chemical Status of Surface Water Bodies of the Dniester River Basin
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Research on identification of chemical status of surface water bodies of the Dniester river basin Final report Project No 538063 Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia July 2019 Research on identification of chemical status of surface water bodies of the Dniester river basin ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Table of contents Executive summary ........................................................................................ 4 1. Sampling points – characteristics ............................................................. 5 2. Metals in surface water and sediment samples ....................................... 7 2.1. Introduction ..................................................................................................................... 7 2.2. Methods .......................................................................................................................... 7 2.3. Surface water samples .................................................................................................... 7 2.4. Sediment samples ........................................................................................................... 8 3. Target, suspect and non-target screening surface water, biota and sediment samples by LC-HR-MS and LC-MS/MS techniques in the Dniester River Basin .................................................................................................... 11 3.1. Introduction ..................................................................................................................
    [Show full text]
  • Green One-Pot Synthesis of Coumarin-Hydroxybenzohydrazide Hybrids and Their Antioxidant Potency
    antioxidants Article Green One-Pot Synthesis of Coumarin-Hydroxybenzohydrazide Hybrids and Their Antioxidant Potency Marko R. Antonijevi´c 1,2, Dušica M. Simijonovi´c 1 , Edina H. Avdovi´c 1,*, Andrija Ciri´c´ 2, Zorica D. Petrovi´c 2, Jasmina Dimitri´cMarkovi´c 3, Višnja Stepani´c 4 and Zoran S. Markovi´c 1,* 1 Department of Science, Institute for Information Technologies, University of Kragujevac, Jovana Cviji´cabb, 34000 Kragujevac, Serbia; [email protected] (M.R.A.); [email protected] (D.M.S.) 2 Department of Chemistry, Faculty of Science, University of Kragujevac, Radoja Domanovi´ca12, 34000 Kragujevac, Serbia; [email protected] (A.C.);´ [email protected] (Z.D.P.) 3 Faculty of Physical Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, Serbia; [email protected] 4 Ruder¯ Boškovi´cInstitute, BijeniˇckaCesta 54, 10000 Zagreb, Croatia; [email protected] * Correspondence: [email protected] (E.H.A.); [email protected] (Z.S.M.); Tel.: +381-34-610-01-95 (Z.S.M.) Abstract: Compounds from the plant world that possess antioxidant abilities are of special im- portance for the food and pharmaceutical industry. Coumarins are a large, widely distributed group of natural compounds, usually found in plants, often with good antioxidant capacity. The coumarin-hydroxybenzohydrazide derivatives were synthesized using a green, one-pot protocol. Citation: Antonijevi´c,M.R.; This procedure includes the use of an environmentally benign mixture (vinegar and ethanol) as a Simijonovi´c,D.M.; Avdovi´c,E.H.; catalyst and solvent, as well as very easy isolation of the desired products.
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Seventeenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION O‹cial from June 28, 2019 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. Printed in Japan The Ministry of Health, Labour and Welfare Ministerial Notification No. 49 Pursuant to Paragraph 1, Article 41 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145, 1960), this notification stated that a part of the Japanese Pharmacopoeia was revised as follows*. NEMOTO Takumi The Minister of Health, Labour and Welfare June 28, 2019 A part of the Japanese Pharmacopoeia (Ministerial Notification No. 64, 2016) was revised as follows*. (The text referred to by the term ``as follows'' are omitted here. All of the revised Japanese Pharmacopoeia in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'' in Supplement 2) are made available for public exhibition at the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmen- tal Health Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan). Supplementary Provisions (Effective Date) Article 1 This Notification is applied from June 28, 2019. (Transitional measures) Article 2 In the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as ``previous Pharmacopoeia'') [limited to those listed in new Pharmacopoeia] and drugs which have been approved as of June 28, 2019 as prescribed under Paragraph 1, Article 14 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
    ICCB-L Plate ICCB-L Therapeutic Absorption Protein FDA Additional info Additional info Vendor_ID Chemical_Name CAS number Therapeutic class Target type Target names (10 mM / 3.33 mM) Well effect tissue binding approved type detail Pharmacological 3712 / 3716 A03 Prestw-1 Azaguanine-8 134-58-7 Oncology Antineoplastic tool 3712 / 3716 A05 Prestw-2 Allantoin 97-59-6 Dermatology Antipsoriatic Carbonic 3712 / 3716 A07 Prestw-3 Acetazolamide 59-66-5 Metabolism Anticonvulsant Enzyme Carbonic anhydrase GI tract Yes anhydrase Potential Plasmatic New therapeutic 3712 / 3716 A09 Prestw-4 Metformin hydrochloride 1115-70-4 Endocrinology Anorectic GI tract Yes anticancer proteins use agent Chemical Plasmatic classification Quaternary 3712 / 3716 A11 Prestw-5 Atracurium besylate 64228-81-5 Neuromuscular Curarizing Yes proteins (according ATC ammonium code) 3712 / 3716 A13 Prestw-6 Isoflupredone acetate 338-98-7 Endocrinology Anti-inflammatory Therapeutic Amiloride-sensitive classification Potassium- 3712 / 3716 A15 Prestw-7 Amiloride hydrochloride dihydrate 17440-83-4 Metabolism Antihypertensive LGIC GI tract Yes sodium channel, ENaC (according ATC sparing agent code) 3712 / 3716 A17 Prestw-8 Amprolium hydrochloride 137-88-2 Infectiology Anticoccidial Veterinary use Poultry Therapeutic Solute carrier family 12 Plasmatic classification Low-ceiling 3712 / 3716 A19 Prestw-9 Hydrochlorothiazide 58-93-5 Metabolism Antihypertensive Carrier GI tract Yes member 3 proteins (according ATC diuretic code) Chemical classification 3712 / 3716 A21 Prestw-10 Sulfaguanidine
    [Show full text]